These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12147151)

  • 1. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes.
    Evans JM; Donnan PT; Morris AD
    Diabet Med; 2002 Aug; 19(8):685-8. PubMed ID: 12147151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.
    Corrao G; Romio SA; Zambon A; Merlino L; Bosi E; Scavini M
    Eur J Clin Pharmacol; 2011 Mar; 67(3):289-99. PubMed ID: 21088829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study.
    Donnan PT; MacDonald TM; Morris AD
    Diabet Med; 2002 Apr; 19(4):279-84. PubMed ID: 11942998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
    Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
    Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Technol Ther; 2004 Feb; 6(1):1-8. PubMed ID: 15000763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
    Quilliam BJ; Ozbay AB; Sill BE; Kogut SJ
    Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
    Kowall B; Rathmann W; Kostev K
    Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced.
    Yamamoto Y; Takahara M; Yasuda T; Katakami N; Matsuoka TA; Kaneto H; Shimomura I
    Endocr J; 2014; 61(9):911-9. PubMed ID: 25048394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.
    Gitt AK; Bramlage P; Schneider S; Tschöpe D
    Cardiovasc Diabetol; 2015 Feb; 14():13. PubMed ID: 25645672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
    Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
    Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.
    Strongman H; D'Oca K; Langerman H; Das R
    Diabetes Obes Metab; 2015 Jun; 17(6):573-580. PubMed ID: 25735201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
    Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
    Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
    Gulliford M; Latinovic R
    Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.